Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

By using a rhesus macaque model of SARS-CoV-2 infection, efficiency of remdesivir was investigated. Rhesus macaques were infected with SARS-CoV-2, and 12 hour later remdesivir was intravenously administered at 10 mg/kg, and thereafter 5 mg/kg remdesivir was treated every 24 hours. This treatment schedule is consistent with that of human patients. The results emphasize the effectiveness of remdesivir for COVID-19 treatment. Initiation of this therapy at the early stage of infection is important.